Click for best price
Meningococcal Disease Drugs Market Size, Share 2022
Market Analysis and Insights: Global Meningococcal Disease Drugs Market
The global Meningococcal Disease Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Meningococcal Disease Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Meningococcal Disease Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Meningococcal Disease Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Meningococcal Disease Drugs market.
Global Meningococcal Disease Drugs Scope and Market Size
Meningococcal Disease Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Meningococcal Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Meningococcal Disease Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Injectable
Oral
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Pfizer
GlaxoSmithKline
Sanofi Pasteur
Novartis
Merck Sharp & Dohme
Hebei Hejia Pharmaceutical Technology Group Co., Ltd
Shandong Jincheng Pharmaceutical Group Co.,ltd.
Apeloa Pharmaceutical Co.,Ltd.
Yiling Pharmaceutical
Baiyunshan Pharmaceutical
SSY Group Limited
Lukang Pharmaceutical Co.,Ltd.
North China Pharmaceutical Company Ltd.
Harbin Pharmaceutical Group Co.,Ltd.
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Meningococcal Disease Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Meningococcal Disease Drugs, with price, sales, revenue, and global market share of Meningococcal Disease Drugs from 2019 to 2022.
Chapter 3, the Meningococcal Disease Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Meningococcal Disease Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Meningococcal Disease Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Meningococcal Disease Drugs.
Chapter 13, 14, and 15, to describe Meningococcal Disease Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Meningococcal Disease Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Meningococcal Disease Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
104 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Meningococcal Disease Drugs Product Introduction
1.2 Global Meningococcal Disease Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Meningococcal Disease Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Meningococcal Disease Drugs Sales in Volume for the Year 2017-2028
1.3 United States Meningococcal Disease Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Meningococcal Disease Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Meningococcal Disease Drugs Sales in Volume for the Year 2017-2028
1.4 Meningococcal Disease Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Meningococcal Disease Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Meningococcal Disease Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Meningococcal Disease Drugs Market Dynamics
1.5.1 Meningococcal Disease Drugs Industry Trends
1.5.2 Meningococcal Disease Drugs Market Drivers
1.5.3 Meningococcal Disease Drugs Market Challenges
1.5.4 Meningococcal Disease Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Meningococcal Disease Drugs Market Segment by Type
2.1.1 Injectable
2.1.2 Oral
2.2 Global Meningococcal Disease Drugs Market Size by Type
2.2.1 Global Meningococcal Disease Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Meningococcal Disease Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Meningococcal Disease Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Meningococcal Disease Drugs Market Size by Type
2.3.1 United States Meningococcal Disease Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Meningococcal Disease Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Meningococcal Disease Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Meningococcal Disease Drugs Market Segment by Application
3.1.1 Hospitals
3.1.2 Drugstores
3.1.3 Others
3.2 Global Meningococcal Disease Drugs Market Size by Application
3.2.1 Global Meningococcal Disease Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Meningococcal Disease Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Meningococcal Disease Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Meningococcal Disease Drugs Market Size by Application
3.3.1 United States Meningococcal Disease Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Meningococcal Disease Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Meningococcal Disease Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Meningococcal Disease Drugs Competitor Landscape by Company
4.1 Global Meningococcal Disease Drugs Market Size by Company
4.1.1 Top Global Meningococcal Disease Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Meningococcal Disease Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Meningococcal Disease Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Meningococcal Disease Drugs Price by Manufacturer (2017-2022)
4.2 Global Meningococcal Disease Drugs Concentration Ratio (CR)
4.2.1 Meningococcal Disease Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Meningococcal Disease Drugs in 2021
4.2.3 Global Meningococcal Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Meningococcal Disease Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Meningococcal Disease Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Meningococcal Disease Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Meningococcal Disease Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Meningococcal Disease Drugs Market Size by Company
4.5.1 Top Meningococcal Disease Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Meningococcal Disease Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Meningococcal Disease Drugs Sales by Players (2020, 2021 & 2022)
5 Global Meningococcal Disease Drugs Market Size by Region
5.1 Global Meningococcal Disease Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Meningococcal Disease Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Meningococcal Disease Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Meningococcal Disease Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Meningococcal Disease Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Meningococcal Disease Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Meningococcal Disease Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Meningococcal Disease Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Meningococcal Disease Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Meningococcal Disease Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Meningococcal Disease Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Meningococcal Disease Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Meningococcal Disease Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Meningococcal Disease Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Meningococcal Disease Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Meningococcal Disease Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Meningococcal Disease Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Corporation Information
7.1.2 Pfizer Description and Business Overview
7.1.3 Pfizer Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Pfizer Meningococcal Disease Drugs Products Offered
7.1.5 Pfizer Recent Development
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Corporation Information
7.2.2 GlaxoSmithKline Description and Business Overview
7.2.3 GlaxoSmithKline Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 GlaxoSmithKline Meningococcal Disease Drugs Products Offered
7.2.5 GlaxoSmithKline Recent Development
7.3 Sanofi Pasteur
7.3.1 Sanofi Pasteur Corporation Information
7.3.2 Sanofi Pasteur Description and Business Overview
7.3.3 Sanofi Pasteur Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Sanofi Pasteur Meningococcal Disease Drugs Products Offered
7.3.5 Sanofi Pasteur Recent Development
7.4 Novartis
7.4.1 Novartis Corporation Information
7.4.2 Novartis Description and Business Overview
7.4.3 Novartis Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Novartis Meningococcal Disease Drugs Products Offered
7.4.5 Novartis Recent Development
7.5 Merck Sharp & Dohme
7.5.1 Merck Sharp & Dohme Corporation Information
7.5.2 Merck Sharp & Dohme Description and Business Overview
7.5.3 Merck Sharp & Dohme Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Merck Sharp & Dohme Meningococcal Disease Drugs Products Offered
7.5.5 Merck Sharp & Dohme Recent Development
7.6 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
7.6.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Corporation Information
7.6.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Description and Business Overview
7.6.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Products Offered
7.6.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development
7.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
7.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Corporation Information
7.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Description and Business Overview
7.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Products Offered
7.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development
7.8 Apeloa Pharmaceutical Co.,Ltd.
7.8.1 Apeloa Pharmaceutical Co.,Ltd. Corporation Information
7.8.2 Apeloa Pharmaceutical Co.,Ltd. Description and Business Overview
7.8.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Products Offered
7.8.5 Apeloa Pharmaceutical Co.,Ltd. Recent Development
7.9 Yiling Pharmaceutical
7.9.1 Yiling Pharmaceutical Corporation Information
7.9.2 Yiling Pharmaceutical Description and Business Overview
7.9.3 Yiling Pharmaceutical Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Yiling Pharmaceutical Meningococcal Disease Drugs Products Offered
7.9.5 Yiling Pharmaceutical Recent Development
7.10 Baiyunshan Pharmaceutical
7.10.1 Baiyunshan Pharmaceutical Corporation Information
7.10.2 Baiyunshan Pharmaceutical Description and Business Overview
7.10.3 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Products Offered
7.10.5 Baiyunshan Pharmaceutical Recent Development
7.11 SSY Group Limited
7.11.1 SSY Group Limited Corporation Information
7.11.2 SSY Group Limited Description and Business Overview
7.11.3 SSY Group Limited Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 SSY Group Limited Meningococcal Disease Drugs Products Offered
7.11.5 SSY Group Limited Recent Development
7.12 Lukang Pharmaceutical Co.,Ltd.
7.12.1 Lukang Pharmaceutical Co.,Ltd. Corporation Information
7.12.2 Lukang Pharmaceutical Co.,Ltd. Description and Business Overview
7.12.3 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Lukang Pharmaceutical Co.,Ltd. Products Offered
7.12.5 Lukang Pharmaceutical Co.,Ltd. Recent Development
7.13 North China Pharmaceutical Company Ltd.
7.13.1 North China Pharmaceutical Company Ltd. Corporation Information
7.13.2 North China Pharmaceutical Company Ltd. Description and Business Overview
7.13.3 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 North China Pharmaceutical Company Ltd. Products Offered
7.13.5 North China Pharmaceutical Company Ltd. Recent Development
7.14 Harbin Pharmaceutical Group Co.,Ltd.
7.14.1 Harbin Pharmaceutical Group Co.,Ltd. Corporation Information
7.14.2 Harbin Pharmaceutical Group Co.,Ltd. Description and Business Overview
7.14.3 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Harbin Pharmaceutical Group Co.,Ltd. Products Offered
7.14.5 Harbin Pharmaceutical Group Co.,Ltd. Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Meningococcal Disease Drugs Industry Chain Analysis
8.2 Meningococcal Disease Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Meningococcal Disease Drugs Distributors
8.3 Meningococcal Disease Drugs Production Mode & Process
8.4 Meningococcal Disease Drugs Sales and Marketing
8.4.1 Meningococcal Disease Drugs Sales Channels
8.4.2 Meningococcal Disease Drugs Distributors
8.5 Meningococcal Disease Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Meningococcal Disease Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Meningococcal Disease Drugs Market Trends
Table 3. Meningococcal Disease Drugs Market Drivers
Table 4. Meningococcal Disease Drugs Market Challenges
Table 5. Meningococcal Disease Drugs Market Restraints
Table 6. Global Meningococcal Disease Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Meningococcal Disease Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Meningococcal Disease Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Meningococcal Disease Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Meningococcal Disease Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Meningococcal Disease Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Meningococcal Disease Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Meningococcal Disease Drugs Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Meningococcal Disease Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Meningococcal Disease Drugs Price by Manufacturer (2017-2022) & (US$/Unit)
Table 16. Global Meningococcal Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Meningococcal Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Disease Drugs as of 2021)
Table 18. Top Players of Meningococcal Disease Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Meningococcal Disease Drugs Product Type
Table 20. Date of International Manufacturers Enter into Meningococcal Disease Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Meningococcal Disease Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Meningococcal Disease Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Meningococcal Disease Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Meningococcal Disease Drugs Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Meningococcal Disease Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Meningococcal Disease Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Meningococcal Disease Drugs Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Meningococcal Disease Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Meningococcal Disease Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Meningococcal Disease Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Meningococcal Disease Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Meningococcal Disease Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Meningococcal Disease Drugs Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Meningococcal Disease Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Meningococcal Disease Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Meningococcal Disease Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Meningococcal Disease Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Meningococcal Disease Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Meningococcal Disease Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Meningococcal Disease Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Pfizer Corporation Information
Table 43. Pfizer Description and Business Overview
Table 44. Pfizer Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 45. Pfizer Meningococcal Disease Drugs Product
Table 46. Pfizer Recent Development
Table 47. GlaxoSmithKline Corporation Information
Table 48. GlaxoSmithKline Description and Business Overview
Table 49. GlaxoSmithKline Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 50. GlaxoSmithKline Product
Table 51. GlaxoSmithKline Recent Development
Table 52. Sanofi Pasteur Corporation Information
Table 53. Sanofi Pasteur Description and Business Overview
Table 54. Sanofi Pasteur Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 55. Sanofi Pasteur Product
Table 56. Sanofi Pasteur Recent Development
Table 57. Novartis Corporation Information
Table 58. Novartis Description and Business Overview
Table 59. Novartis Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 60. Novartis Product
Table 61. Novartis Recent Development
Table 62. Merck Sharp & Dohme Corporation Information
Table 63. Merck Sharp & Dohme Description and Business Overview
Table 64. Merck Sharp & Dohme Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 65. Merck Sharp & Dohme Product
Table 66. Merck Sharp & Dohme Recent Development
Table 67. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Corporation Information
Table 68. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Description and Business Overview
Table 69. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 70. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Product
Table 71. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development
Table 72. Shandong Jincheng Pharmaceutical Group Co.,ltd. Corporation Information
Table 73. Shandong Jincheng Pharmaceutical Group Co.,ltd. Description and Business Overview
Table 74. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 75. Shandong Jincheng Pharmaceutical Group Co.,ltd. Product
Table 76. Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development
Table 77. Apeloa Pharmaceutical Co.,Ltd. Corporation Information
Table 78. Apeloa Pharmaceutical Co.,Ltd. Description and Business Overview
Table 79. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 80. Apeloa Pharmaceutical Co.,Ltd. Product
Table 81. Apeloa Pharmaceutical Co.,Ltd. Recent Development
Table 82. Yiling Pharmaceutical Corporation Information
Table 83. Yiling Pharmaceutical Description and Business Overview
Table 84. Yiling Pharmaceutical Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 85. Yiling Pharmaceutical Product
Table 86. Yiling Pharmaceutical Recent Development
Table 87. Baiyunshan Pharmaceutical Corporation Information
Table 88. Baiyunshan Pharmaceutical Description and Business Overview
Table 89. Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 90. Baiyunshan Pharmaceutical Product
Table 91. Baiyunshan Pharmaceutical Recent Development
Table 92. SSY Group Limited Corporation Information
Table 93. SSY Group Limited Description and Business Overview
Table 94. SSY Group Limited Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 95. SSY Group Limited Product
Table 96. SSY Group Limited Recent Development
Table 97. Lukang Pharmaceutical Co.,Ltd. Corporation Information
Table 98. Lukang Pharmaceutical Co.,Ltd. Description and Business Overview
Table 99. Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 100. Lukang Pharmaceutical Co.,Ltd. Product
Table 101. Lukang Pharmaceutical Co.,Ltd. Recent Development
Table 102. North China Pharmaceutical Company Ltd. Corporation Information
Table 103. North China Pharmaceutical Company Ltd. Description and Business Overview
Table 104. North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 105. North China Pharmaceutical Company Ltd. Product
Table 106. North China Pharmaceutical Company Ltd. Recent Development
Table 107. Harbin Pharmaceutical Group Co.,Ltd. Corporation Information
Table 108. Harbin Pharmaceutical Group Co.,Ltd. Description and Business Overview
Table 109. Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. Harbin Pharmaceutical Group Co.,Ltd. Product
Table 111. Harbin Pharmaceutical Group Co.,Ltd. Recent Development
Table 112. Key Raw Materials Lists
Table 113. Raw Materials Key Suppliers Lists
Table 114. Meningococcal Disease Drugs Customers List
Table 115. Meningococcal Disease Drugs Distributors List
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Meningococcal Disease Drugs Product Picture
Figure 2. Global Meningococcal Disease Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Meningococcal Disease Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Meningococcal Disease Drugs Sales 2017-2028 (K Units)
Figure 5. United States Meningococcal Disease Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Meningococcal Disease Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Meningococcal Disease Drugs Sales 2017-2028 (K Units)
Figure 8. United States Meningococcal Disease Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Meningococcal Disease Drugs Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Meningococcal Disease Drugs Report Years Considered
Figure 11. Product Picture of Injectable
Figure 12. Product Picture of Oral
Figure 13. Global Meningococcal Disease Drugs Market Share by Type in 2022 & 2028
Figure 14. Global Meningococcal Disease Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 15. Global Meningococcal Disease Drugs Sales Market Share in Value by Type (2017-2028)
Figure 16. Global Meningococcal Disease Drugs Sales by Type (2017-2028) & (K Units)
Figure 17. Global Meningococcal Disease Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 18. Global Meningococcal Disease Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 19. United States Meningococcal Disease Drugs Market Share by Type in 2022 & 2028
Figure 20. United States Meningococcal Disease Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 21. United States Meningococcal Disease Drugs Sales Market Share in Value by Type (2017-2028)
Figure 22. United States Meningococcal Disease Drugs Sales by Type (2017-2028) & (K Units)
Figure 23. United States Meningococcal Disease Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 24. United States Meningococcal Disease Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 25. Product Picture of Hospitals
Figure 26. Product Picture of Drugstores
Figure 27. Product Picture of Others
Figure 28. Global Meningococcal Disease Drugs Market Share by Application in 2022 & 2028
Figure 29. Global Meningococcal Disease Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 30. Global Meningococcal Disease Drugs Sales Market Share in Value by Application (2017-2028)
Figure 31. Global Meningococcal Disease Drugs Sales by Application (2017-2028) & (K Units)
Figure 32. Global Meningococcal Disease Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 33. Global Meningococcal Disease Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 34. United States Meningococcal Disease Drugs Market Share by Application in 2022 & 2028
Figure 35. United States Meningococcal Disease Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 36. United States Meningococcal Disease Drugs Sales Market Share in Value by Application (2017-2028)
Figure 37. United States Meningococcal Disease Drugs Sales by Application (2017-2028) & (K Units)
Figure 38. United States Meningococcal Disease Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 39. United States Meningococcal Disease Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 40. North America Meningococcal Disease Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 41. North America Meningococcal Disease Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 42. United States Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 43. Canada Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 44. Europe Meningococcal Disease Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 45. Europe Meningococcal Disease Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 46. Germany Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. France Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. U.K. Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Italy Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Russia Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Asia-Pacific Meningococcal Disease Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 52. Asia-Pacific Meningococcal Disease Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 53. China Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Japan Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. South Korea Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. India Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Australia Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. China Taiwan Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Indonesia Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Thailand Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Malaysia Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Latin America Meningococcal Disease Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 63. Latin America Meningococcal Disease Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 64. Mexico Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Brazil Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Argentina Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Middle East & Africa Meningococcal Disease Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 68. Middle East & Africa Meningococcal Disease Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 69. Turkey Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Saudi Arabia Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. UAE Meningococcal Disease Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Meningococcal Disease Drugs Value Chain
Figure 73. Meningococcal Disease Drugs Production Process
Figure 74. Channels of Distribution
Figure 75. Distributors Profiles
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
